249 related articles for article (PubMed ID: 27289577)
1. [Determination of in vitro synergy by a checkerboard method when 3 core antimicrobial agents of the retreatment new scheme combined against MDR-MTB and XDR-MTB].
Zhang LL; Yang H; Xiao HP; Lu JM; Sha W; Zhang Q
Zhonghua Jie He He Hu Xi Za Zhi; 2016 Jun; 39(6):464-8. PubMed ID: 27289577
[TBL] [Abstract][Full Text] [Related]
2. In vitro Synergism of Six Antituberculosis Agents Against Drug-Resistant
Ying R; Huang X; Gao Y; Wang J; Liu Y; Sha W; Yang H
Infect Drug Resist; 2021; 14():3729-3736. PubMed ID: 34548797
[TBL] [Abstract][Full Text] [Related]
3. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates.
Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD
J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332
[TBL] [Abstract][Full Text] [Related]
4. Synergistic activities of clofazimine with moxifloxacin or capreomycin against Mycobacterium tuberculosis in China.
Li G; Xu Z; Jiang Y; Liu H; Zhao LL; Li M; Xu D; Zhao X; Liu Z; Wang R; Wan K
Int J Antimicrob Agents; 2019 Nov; 54(5):642-646. PubMed ID: 31200023
[TBL] [Abstract][Full Text] [Related]
5. Laboratory evaluation of the Anyplex™ II MTB/MDR and MTB/XDR tests based on multiplex real-time PCR and melting-temperature analysis to identify Mycobacterium tuberculosis and drug resistance.
Igarashi Y; Chikamatsu K; Aono A; Yi L; Yamada H; Takaki A; Mitarai S
Diagn Microbiol Infect Dis; 2017 Dec; 89(4):276-281. PubMed ID: 28974394
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of (-)-deoxypergularinine, on its own and in combination with anti-tubercular drugs, against resistant strains of Mycobacterium tuberculosis.
Nam KW; Jang WS; Jyoti MA; Kim S; Lee BE; Song HY
Phytomedicine; 2016 May; 23(5):578-82. PubMed ID: 27064017
[TBL] [Abstract][Full Text] [Related]
7. Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.
Davies Forsman L; Giske CG; Bruchfeld J; Schön T; Juréen P; Ängeby K
Int J Mycobacteriol; 2015 Mar; 4 Suppl 1():80-1. PubMed ID: 27128620
[TBL] [Abstract][Full Text] [Related]
8. Minimum inhibitory concentrations of rifampin and isoniazid among multidrug and isoniazid resistant Mycobacterium tuberculosis in Ethiopia.
Getahun M; Blumberg HM; Ameni G; Beyene D; Kempker RR
PLoS One; 2022; 17(9):e0274426. PubMed ID: 36099255
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of rifabutin and rifampin against clinical isolates of Mycobacterium tuberculosis in Taiwan.
Chien HP; Yu MC; Ong TF; Lin TP; Luh KT
J Formos Med Assoc; 2000 May; 99(5):408-11. PubMed ID: 10870331
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of antimicrobial combinations against clinical isolates of susceptible and resistant Mycobacterium tuberculosis.
Bergmann JS; Woods GL
Int J Tuberc Lung Dis; 1998 Aug; 2(8):621-6. PubMed ID: 9712275
[TBL] [Abstract][Full Text] [Related]
11. New treatment options for multidrug-resistant tuberculosis.
Field SK; Fisher D; Jarand JM; Cowie RL
Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676
[TBL] [Abstract][Full Text] [Related]
12. Determination of in vitro synergy between linezolid and other antimicrobial agents against Mycobacterium tuberculosis isolates.
Zou L; Liu M; Wang Y; Lu J; Pang Y
Tuberculosis (Edinb); 2015 Dec; 95(6):839-842. PubMed ID: 26395151
[TBL] [Abstract][Full Text] [Related]
13. No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis.
Pang Y; Jing W; Lu J; Zong Z; Huo F; Dong L; Dai G; Li Y; Huang H; Chu N
Diagn Microbiol Infect Dis; 2019 Aug; 94(4):361-364. PubMed ID: 30876684
[TBL] [Abstract][Full Text] [Related]
14. In vitro efficacy of 21 dual antimicrobial combinations comprising novel and currently recommended combinations for treatment of drug resistant gonorrhoea in future era.
Singh V; Bala M; Bhargava A; Kakran M; Bhatnagar R
PLoS One; 2018; 13(3):e0193678. PubMed ID: 29509792
[TBL] [Abstract][Full Text] [Related]
15. [Present and future in the use of anti-tubercular drugs].
Didilescu C; Craiova UM
Pneumologia; 2011; 60(4):198-201. PubMed ID: 22420168
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effect of two combinations of antituberculous drugs against Mycobacterium tuberculosis.
Rey-Jurado E; Tudó G; Martínez JA; González-Martín J
Tuberculosis (Edinb); 2012 May; 92(3):260-3. PubMed ID: 22342247
[TBL] [Abstract][Full Text] [Related]
17. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model.
Poissy J; Aubry A; Fernandez C; Lott MC; Chauffour A; Jarlier V; Farinotti R; Veziris N
Antimicrob Agents Chemother; 2010 Nov; 54(11):4765-71. PubMed ID: 20805388
[TBL] [Abstract][Full Text] [Related]
18. In vitro synergistic activity of clofazimine and other antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis isolates.
Zhang Z; Li T; Qu G; Pang Y; Zhao Y
Int J Antimicrob Agents; 2015 Jan; 45(1):71-5. PubMed ID: 25459737
[TBL] [Abstract][Full Text] [Related]
19. Effects of the encapsulation of usnic acid into liposomes and interactions with antituberculous agents against multidrug-resistant tuberculosis clinical isolates.
Ferraz-Carvalho RS; Pereira MA; Linhares LA; Lira-Nogueira MC; Cavalcanti IM; Santos-Magalhães NS; Montenegro LM
Mem Inst Oswaldo Cruz; 2016 May; 111(5):330-4. PubMed ID: 27143488
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Park SK; Kim JH; Kang H; Cho JS; Smego RA
Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
